DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vivelle-DOT (Estradiol) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

      ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant Neoplasms, Endometrial Cancer.)

                CARDIOVASCULAR AND OTHER RISKS

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular Disorders.)

      The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age), during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL PHARMACOLOGY, Clinical Studies).

The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)

      Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

 

VIVELLE-DOT SUMMARY

Vivelle-Dot

Vivelle-Dot® (estradiol transdermal system) contains estradiol in a multipolymeric adhesive. The system is designed to release estradiol continuously upon application to intact skin.

Vivelle-Dot® (estradiol transdermal system) is indicated in:

  1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause.
  2. Treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
  3. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
  4. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risks of osteoporosis and non-estrogen medications should be carefully considered.

The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.


See all Vivelle-DOT indications & dosage >>

VIVELLE-DOT NEWS HIGHLIGHTS

Media Articles Related to Vivelle-DOT (Estradiol)

Antiangiogenic Role Of 2ME2 Demonstrated In Rheumatoid Arthritis Models
Source: Arthritis / Rheumatology News From Medical News Today [2008.11.04]

Hormone Cream Smoothes Skin Not Damaged by Sun
Source: MedPage Today Dermatology [2008.09.15]

FDA Drug and Device Approvals: June 10, 2004
Source: Medscape Pharmacotherapy Headlines [2004.06.10]

more >>

Published Studies Related to Vivelle-DOT (Estradiol)

Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. [2008.10]

Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. [2008.09]

Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]

A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. [2008.08]

Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. [2008.08]

more >>

Clinical Trials Related to Vivelle-DOT (Estradiol)

Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women [Completed]

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climaraź Transdermal System 0.025 mg/Day [Completed]

Treatment of Hot Flushes in Asian Women With Ultra-Low Dose Estradiol Patch [Completed]

Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination [Completed]

Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer [Completed]

more >>

VIVELLE-DOT PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 3 ratings/reviews, Vivelle-DOT has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Vivelle-DOT review by 61 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   menopausal symptoms
Dosage & duration:   0.0375 mg patch taken twice per week for the period of 2.5 months
Other conditions:   allergies and ocular hypertension
Other drugs taken:   Fexofenedine and Xalatan
  
Reported Results
Benefits:   I had recently developed hotflashes which were becoming notceably worse. Very shortly after beginning this drug, my hot flashes stopped. I am hoping there are other benefits like preserving the integrity of my body, but it may be too soon to tell. It definitely alleviated the hot flashes, however.
Side effects:   None that I have noticed, so far.
Comments:   This drug comes in a very small patch which you change every three to four days. It's worn on the lower abdomen. That's it. You really can't feel it, and don't even know it's there.

 

Vivelle-DOT review by 54 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   low estragen
Dosage & duration:   lowest (dosage frequency: twice a week) for the period of year and half
Other conditions:   none
Other drugs taken:   advair
  
Reported Results
Benefits:   I had more energy, better disposition and I slept better. This hormone therapy is great. I think most menopausal women should take it. It made me feel more like my old self.
Side effects:   I had absolutely no side effects.
Comments:   I put on a new patch twice a week. I recommend Vivelle Dot to most women.

 

Vivelle-DOT review by 54 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   low estragen
Dosage & duration:   lowest (dosage frequency: twice a week) for the period of year and half
Other conditions:   none
Other drugs taken:   advair
  
Reported Results
Benefits:   I had more energy, better disposition and I slept better. This hormone therapy is great. I think most menopausal women should take it. It made me feel more like my old self.
Side effects:   I had absolutely no side effects.
Comments:   I put on a new patch twice a week. I recommend Vivelle Dot to most women.

See all Vivelle-DOT reviews / ratings >>

Page last updated: 2008-11-04

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008